Braveheart Bio (BRVE) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases.

• Lead product candidate BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor, targets both obstructive and non-obstructive HCM.

• BHB-1893 was in-licensed from Jiangsu Hengrui Pharmaceuticals, with all clinical trials to date conducted by Hengrui, primarily in China.

• Plans to advance BHB-1893 through global Phase 3 trials in oHCM and nHCM, with additional pipeline expansion into related indications.

Financial performance and metrics

• Net loss of $66.1 million for the year ended December 31, 2025, and $14.3 million for the three months ended March 31, 2026.

• Accumulated deficit of $80.3 million as of March 31, 2026.

• Cash and cash equivalents of $80.6 million as of March 31, 2026.

• Operating expenses primarily driven by research and development and in-process R&D related to the Hengrui license.

• Raised $185 million from leading life sciences investors since inception.

Use of proceeds and capital allocation

• Net proceeds from the IPO, together with existing cash, will fund Phase 3 trials for BHB-1893 in oHCM and nHCM, R&D personnel and overhead, and general corporate purposes.

• May use a portion of proceeds for in-licensing, acquisitions, or investments in complementary businesses or technologies.